Antibody ID	ANI0TKWDN
Antibody Name	Thio hu anti-CD22 10F4v3 LC K149C
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	B-cell receptor CD22 (CD22)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.56%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.16%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.19%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.65%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.58%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ug/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 6%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (12 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.12%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.75%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.27%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (4 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.28%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.34%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.59%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (8 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 34.22%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 15 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 26.83%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.70%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.92%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.81%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.38%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.68 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.39 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	42.92 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2650.34 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5156.08 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6434.14 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 43.13%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.14%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.73%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.54%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.06%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 23.58%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 2 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.56 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.7 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.7 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44.5 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.4 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	234.11 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 7 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	254.2 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 8 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1303.63 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.05%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68.38%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.44%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.38%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.69%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.71%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.76%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Ref 1	Silvestrol antibody-drug conjugates and methods of use; 2017-12-14.
Ref 2	Pyrrolobenzodiazepine antibody drug conjugates and methods of use; 2017-04-06.